Recruiting

1H MRS with 2H-Glucose

Sponsor:

UCLA

Code:

NCT06594315

Conditions

Glioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Deuterated Glucose

Magnetic Resonance Imaging (MRI)

Blood Sample

MR spectroscopy (MRS)

Study Details

Brief summary:

This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.

Conditions

Glioma

Study ID

NCT06594315

Start date

Jul 20, 2022

Status verified date

Aug, 2026

Completion date

Jul 31, 2027

Anticipated

Primary completion date

Jul 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Participants must be >= 18 years old

  • Cohort 1: Healthy controls
  • Cohort 2: Participants with histological proven glioma who have evidence of evaluable disease (with contrast enhancing lesion or non-enhancing lesion > 4 cc) based on a prior MR scan.
  • Cohort 3: Participants with histologically proven glioma who will be undergoing any treatment.
2. Participants must not have any significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the subject's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent.
3. Participants must not be pregnant or breast-feeding. Persons of childbearing potential are required to obtain a negative serum or urine pregnancy test within 14 days of the scan. Effective contraception (men and women) must be used in subjects of childbearing potentials.
4. Participants must sign an informed consent indicating that they are aware of the investigational nature of the study

Exclusion Criteria:

Participants must be excluded from participating in this study if they are not able to comply with the study and/or follow-up procedures.

1. Participants exceeding the weight limitations of the scanner (300 pounds)
2. Inability to lie still for the entire imaging time (e.g., cough, severe arthritis, etc.)
3. Inability to complete the study due to other reasons (severe claustrophobia, MR incompatible medical implants or devices, inability to comply with pre-procedure fasting, etc.)
4. Pre-examination blood glucose level of > 120 mg/dL as measured by point of care finger stick blood glucose test prior to MR examination.
5. Participants, either healthy volunteers (recruited for cohort 1) or participants with glioma (for cohorts 2 \&3), have history of diabetes mellitus.

Study Design

Enrollment

80 participants

Anticipated

Interventions and Outcome Measures

Arms

Cohort 1: Healthy Controls

Twenty healthy controls for will have 2H-glucose metabolism in measured for development of robust strategy in optimizing acquisition parameters.

Cohort 2: Glioma participants (Single Time point)

Thirty participants with glioma who may or may not have received prior treatment for testing the optimized imaging protocol developed in Cohort 1.

Cohort 3: Glioma participants (Multiple Time points)

Thirty participants who will receive non-investigational treatment for glioma enrolled to test the evaluation for treatment induced metabolic changes at baseline and post- non-investigational treatment.

Interventions

Deuterated Glucose

Given orally

Magnetic Resonance Imaging (MRI)

Imaging procedure performed at University of California, San Francisco

Blood Sample

Capillary blood from the fingertip

MR spectroscopy (MRS)

Imaging procedure performed at University of California, San Francisco

Primary outcome measure

  • Signal-to-noise ratio (Cohort 1 & 2) [ Time Frame: Day of imaging (1 day) ]
  • Mean difference in metabolite concentrations (Cohort 1 & 2) [ Time Frame: Day of imaging (1 day) ]
  • Mean difference in fractional enrichment (Cohort 1 & 2) [ Time Frame: Day of imaging (1 day) ]
  • Mean metabolic turnover over time (Cohort 3) [ Time Frame: Up to 21 days after the completion of non-investigational treatment ]

Central Contacts and Locations

Central contacts

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Principal Investigator:

Yan Li, PhD

More Information

Sponsor

University of California, San Francisco

Last update posted

Sep 2, 2026

Last verified

Aug, 2026

Keywords

  • Glucose Metabolism

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-09-02.